

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Aeterna Zentaris Inc.  
Form 6-K  
March 03, 2006

FORM 6-K  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of March 2006

AETERNA ZENTARIS INC.

-----  
1405, boul. du Parc-Technologique  
Quebec, Quebec  
Canada, G1P 4P5  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F.

Form 20-F                      Form 40-F      X  
-----                                      -----

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes                                      No      X  
-----                                      -----

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g3-2(b): 82-  
-----

DOCUMENTS INDEX

DOCUMENTS	DESCRIPTION
-----	-----
1.	Press release dated March 1, 2006: AEtterna Zentaris Reports 2005 Fourth Quarter and Full-Year Financial and Operating Results

[AETERNA ZENTARIS LOGO]

AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.  
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881  
www.aeternazentaris.com

PRESS RELEASE  
For immediate release

AETERNA ZENTARIS REPORTS 2005 FOURTH QUARTER AND FULL-YEAR  
FINANCIAL AND OPERATING RESULTS

COMPANY HIGHLIGHTS SIGNIFICANT MILESTONES IN 2005 AND RECENT ACHIEVEMENTS

ALL AMOUNTS ARE IN U.S. DOLLARS

FULL-YEAR 2005 HIGHLIGHTS

CONSOLIDATED FINANCIAL RESULTS

- Revenues increased by 38% to \$247.4 million, compared to \$179.2 million in 2004;
- R&D net of tax credits and grants of \$27 million, compared to \$23.3 million in 2004;
- Earnings from operations of \$14.4 million, compared to \$13.2 million in 2004;
- Net earnings of \$10.6 million, compared to a net loss of \$4.4 million in 2004;
- Cash and short-term investments of \$52.7 million as of December 31, 2005; and
- Change of reporting currency to U.S. dollars.

PRODUCT DEVELOPMENT PIPELINE ADVANCEMENTS

- Cetrorelix: Initiation of pivotal clinical program in endometriosis by partner, Solvay and Phase 2 trial in benign prostate hyperplasia (BPH) by partner, Shionogi/Nippon Kayaku;
- Ozarelix: Initiation of Phase 2 trials for BPH and prostate cancer in Europe sponsored by partner, Spectrum -- completion of patient recruitment for both studies ahead of schedule and initiation of Phase

## Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

1/2 trial for prostate cancer in the U.S.; and

- Perifosine: Initiation of a Phase 2 trial in non-small cell lung cancer in Europe, disclosure of positive Phase 2 trial results in prostate cancer by partner, Keryx, and initiation of multiple Phase 1/2 trials for multiple cancers by partner, Keryx.

[AETERNA ZENTARIS LOGO]

### CORPORATE AFFAIRS

- AEterna Zentaris: Acquisition of Echelon Biosciences Inc., U.S.; and
- Subsidiary, Atrium: Successful IPO (TSX: ATB.sv), as well as two accretive acquisitions -- MultiChem (Canada) and Douglas (U.S.).

QUEBEC CITY, CANADA, MARCH 1, 2006 - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today reported financial and operating results for the fourth quarter and full year ended December 31, 2005. Consolidated revenues for the fourth quarter 2005 were \$72.5 million, an increase of 65% compared to total revenues of \$43.9 million for the same period in 2004. Consolidated R&D expenses net of tax credits amounted to \$8.3 million for the fourth quarter of 2005 compared to \$5.8 million for the same period in 2004.

Consolidated net earnings from operations for the fourth quarter 2005 were \$3.5 million, compared to \$0.9 million for the same period in 2004. The Company's consolidated net earnings were \$0.9 million for the fourth quarter of 2005, or \$0.02 per share, compared to a net loss of \$2 million, or \$0.04 per share for the same period in 2004. The consolidated cash and short-term investments were \$52.7 million for the period ended December 31, 2005.

### CONSOLIDATED RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2005

Consolidated revenues for the 12-month period ended December 31, 2005 increased by 38% to \$247.4 million, compared to \$179.2 million for the same period in 2004. Consolidated R&D expenses net of tax credits were \$27 million in 2005, compared to \$23.3 million for the same period in 2004 due to the Company's advancements in its product pipeline with a particular effort on cetorelix, ozarelix, and perifosine.

The Company reported consolidated earnings from operations for the 12-month period ended December 31, 2005 of \$14.4 million, compared to \$13.2 million for the same period in 2004. Consolidated net earnings for the 12-month period ended December 31, 2005 were \$10.6 million, or \$0.23 per share, compared to a net loss of \$4.4 million, or \$0.10 per share, for the same period in 2004. The increase of the net earnings is attributed to a gain on dilution of investments of \$19 million related to the Initial Public Offering and the issuance of Subordinate Voting Shares of the Company's subsidiary, Atrium Biotechnologies Inc. (TSX: ATB.sv) during 2005. Excluding this \$19 million gain on dilution that occurred, the Company would have generated a consolidated net loss of \$8.4 million or \$0.18 per share. As compared to last year's net loss of \$4.4 million, this \$4 million loss increase is mainly attributable to increased R&D expense, non-cash stock-based compensation costs and interest expense.

"Over the past year, we made great strides in advancing our lead product development candidates, cetorelix, ozarelix and perifosine through the

## Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

pipeline. With our focused strategy in place, we are pleased to have launched, alone or in collaboration with our partners, more than seven advanced-stage clinical trials and will continue to aggressively advance our pipeline in 2006," said Gilles Gagnon, AETerna Zentaris' President and Chief Executive Officer.

2

[AETERNA ZENTARIS LOGO]

Dennis Turpin, Vice President and Chief Financial Officer of AETerna Zentaris, added: "With a controlled burn-rate, revenues from two marketed products and strategic alliances, the recent conversion of all our convertible term loans, as well as leverage from our stake in our profitable subsidiary Atrium, the Company is financially sound and well positioned to carry on our focused business strategy. Our consolidated cash and short-term position remains strong at \$52.7 million as of December 31, 2005. In 2006, while maintaining a solid financial position, we expect our R&D investment to increase, reflecting our commitment to expand and advance our clinical-stage pipeline, in particular, the oncology proprietary products."

### RECENT ACHIEVEMENTS (EARLY 2006)

#### FINANCIAL

- Strategic shareholders: The Solidarity Fund QFL and SGF Sante Inc., exercised prematurely the right to convert the entirety of their term loans into AETerna Zentaris common shares.

#### PRODUCT DEVELOPMENT PIPELINE ADVANCEMENTS

- Cetorelix: Regained BPH rights from Solvay without financial compensation payable; and
- Perifosine: Initiation of Phase 2, multi-center study for the treatment of refractory multiple myeloma by partner, Keryx.

#### COMPANY OUTLOOK FOR 2006

- Cetorelix: Continue to pursue late-stage clinical development programs in endometriosis with partner, Solvay.
  - o Disclose results from Japanese Phase 2 trial in BPH with partner, Shionogi/Nippon Kayaku.
  - o Initiate late-stage program for BPH in North America;
- Ozarelix: Disclose Phase 2 trial results in BPH and prostate cancer with partner, Spectrum;
- Perifosine: Begin to disclose results from the extensive Phase I/2 trial program ongoing in monotherapy and combination therapy for multiple forms of cancer with partner, Keryx, while completing patient recruitment for the Company's current combination with radiotherapy Phase 2 trial in non-small cell lung cancer;
- AN-152 cytotoxic-conjugate: Disclose results from Phase 1 trial in gynaecological cancers in patients with confirmed LHRH-receptor;

## Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

- Tubulin inhibitors program: Initiate Phase 1 trial in cancer in the U.S.;
- Additional accretive strategic alliances with selected partners.

3

[AETERNA ZENTARIS LOGO]

"We believe, as we continue to focus our development efforts and commit our resources to advancing our pipeline, we will become a late-stage biopharmaceutical company with a clear focus on oncology and endocrinology within the next 12 to 18 months. Additionally, our subsidiary, Atrium, has again demonstrated its ability to execute its aggressive acquisition strategy and continues to yield excellent year-over-year growth in all of its activity sectors. It is our intention to continue to set the stage for our long-term strategy of emerging as a fully-integrated, global specialty pharmaceutical company," concluded Mr. Gagnon.

### CONFERENCE CALL INFORMATION

Management will be hosting a conference call for the investment community beginning at 10:30 a.m. Eastern Standard Time today, Wednesday, March 1, to discuss 2005 fourth quarter and full-year financial and operating results followed by a question and answer session.

To participate in the live conference call by telephone, please dial 514-807-8791, 416-640-4127 from Canada or 800-814-4941 from outside Canada. Individuals interested in listening to the conference call on the Internet may do so by visiting [www.aeternazentaris.com](http://www.aeternazentaris.com). A replay will be available on the

-----  
Company's Web site for 30 days.

### ABOUT AETERNA ZENTARIS INC.

AEterna Zentaris Inc. is a growing global biopharmaceutical company focused on oncology and endocrine therapy with proven expertise in drug discovery, development and commercialization.

AEterna Zentaris also owns 48.4% of the equity of Atrium Biotechnologies Inc. (TSX: ATB.sv) and 64.8% of its voting rights. Atrium is a developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutritional industries.

News releases and additional information are available at [www.aeternazentaris.com](http://www.aeternazentaris.com).

### FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those

## Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

-30-

4

[AETERNA ZENTARIS LOGO]

### CONTACTS

#### MEDIA RELATIONS

Paul Burroughs  
(418) 652-8525 ext. 406  
paul.burroughs@aeternazentaris.com  
-----

#### INVESTOR RELATIONS

Jenene Thomas  
(418) 655-6420 or (908) 996-3154  
jenene.thomas@aeternazentaris.com  
-----

ATTACHMENT: Financial summary

5

[AETERNA ZENTARIS LOGO]

(IN THOUSANDS OF US DOLLARS, EXCEPT SHARE AND PER SHARE DATA)

### CONSOLIDATED RESULTS

UNAUDITED	QUARTERS ENDED DECEMBER 31,		YEARS DECEMBER
	2005	2004	2005
	\$	\$	\$
REVENUES	72,501	43,891	247,389
OPERATING EXPENSES			
Cost of sales	46,565	25,916	156,365
Selling, general and administrative	12,252	9,456	42,037
R&D costs, net of tax credits and grants	8,279	5,803	26,971
Depreciation and amortization	1,938	1,802	7,604

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

	69,034	42,977	232,977
EARNINGS FROM OPERATIONS	3,467	914	14,412
Interest income	514	291	1,601
Interest expense	(2,719)	(1,742)	(9,785)
Foreign exchange loss	105	(433)	(263)
EARNINGS (LOSS) BEFORE THE FOLLOWING ITEMS	1,367	(970)	5,965
Current income taxes	(646)	(177)	(5,149)
Future income taxes	(268)	327	(2,183)
Gain (loss) on dilution of investments	2,500	(81)	19,002
Non-controlling interest	(2,017)	(1,102)	(7,064)
NET EARNINGS (LOSS) FOR THE PERIOD	936	(2,003)	10,571
NET EARNINGS (LOSS) PER SHARE			
Basic	0.02	(0.04)	0.23
Diluted	0.02	(0.04)	0.22
Weighted average number of shares			
Basic	46,139,814	45,650,742	46,139,814
Diluted	46,379,336	46,124,784	46,459,131
Issued and outstanding shares			46,139,814

6

[AETERNA ZENTARIS LOGO]

CONSOLIDATED BALANCE SHEET UNAUDITED	AS AT DECEMBER 31, 2005
	\$
Cash and short-term investments	52,705
Other current assets	108,998
Long term assets	161,703
Total assets	263,835
Current liabilities	425,538
Long-term debt	62,201
Other long-term liabilities	135,743
	53,532

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Non-controlling interest	64,531
	-----
Shareholders' equity	316,007
	109,531
	-----
Total liabilities and shareholders' equity	425,538
	-----
	-----

7

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

Date: March 2, 2006

-----

By: /s/ Mario Paradis

-----

Mario Paradis  
Senior Finance Director and  
Corporate Secretary